During the Veeva R&D and Quality Summit held in Madrid last month, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to discuss the event and i
Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a